方盛制药：吲哚布芬片获得《药品注册证书》

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received approval from the National Medical Products Administration for its drug, Indobufen Tablets, allowing for production [1] Group 1 - The company has obtained a drug registration certificate for Indobufen Tablets, which is a derivative of indole butyric acid and acts as a platelet aggregation inhibitor [1]